Cargando…

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

BACKGROUND: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs. We aimed to evaluate the acid-inhibitory effects and efficacy of a novel potassium-competitive acid blocker (vonoprazan) in patients with PPI-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwakiri, Katsuhiko, Sakurai, Yuuichi, Shiino, Madoka, Okamoto, Hiroyuki, Kudou, Kentaro, Nishimura, Akira, Hiramatsu, Naoki, Umegaki, Eiji, Ashida, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424876/ https://www.ncbi.nlm.nih.gov/pubmed/28567114 http://dx.doi.org/10.1177/1756283X17705329

Ejemplares similares

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2016)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2019)

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
por: Sakurai, Yuuichi, et al.
Publicado: (2016)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers
por: Takahashi, Kazuya, et al.
Publicado: (2016)

The role of vonoprazan in patients with erosive esophagitis
por: Zhang, Mengyu, et al.
Publicado: (2022)

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study
por: Kawai, Takashi, et al.
Publicado: (2018)

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease
por: Niikura, Ryota, et al.
Publicado: (2018)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
por: Mizokami, Yuji, et al.
Publicado: (2018)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

Cardiovascular effect of dental anesthesia with articaine (40 mg with epinefrine 0,5 mg % and 40 mg with epinefrine 1 mg%) versus mepivacaine (30mg and 20 mg with epinefrine 1 mg%) in medically compromised cardiac patients: A cross-over, randomized, single blinded study
por: Torres-Lagares, Daniel, et al.
Publicado: (2012)

Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: The OITA-GF study 2
por: Tamura, Akira, et al.
Publicado: (2013)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis
por: Yang, Sensen, et al.
Publicado: (2022)

To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
por: Agrawal, Deepak, et al.
Publicado: (2018)

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review
por: Chinzon, Décio, et al.
Publicado: (2021)

The effect of proton pump inhibitors and vonoprazan on the development of ‘gastric mucosal redness’
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Spin pumping in magnetic trilayer structures with an MgO barrier
por: Baker, A. A., et al.
Publicado: (2016)

EUV stimulated emission from MgO pumped by FEL pulses
por: Jonnard, Philippe, et al.
Publicado: (2017)

Gastroduodenal Intussusception Due to Vonoprazan-induced Gastric Polyps
por: Nishimura, Naoyuki, et al.
Publicado: (2021)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
por: Sakata, Yasuhisa, et al.
Publicado: (2014)

Pretreatment and gaseous radiocarbon dating of 40–100 mg archaeological bone
por: Fewlass, H., et al.
Publicado: (2019)

Genome Sequence of Salmonella enterica Serovar Typhimurium Bacteriophage MG40
por: Gilcrease, Eddie B., et al.
Publicado: (2020)

Computational investigation of the Mg-ion conductivity and phase stability of MgZr(4)(PO(4))(6)
por: Nakano, Koki, et al.
Publicado: (2019)

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice
por: Bramlage, Peter, et al.
Publicado: (2013)

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
por: Liang, Chih-Ming, et al.
Publicado: (2017)

Efficacy of 4.0 mg versus 0.4 mg Folic Acid Supplementation on the Reproductive Outcomes: A Randomized Controlled Trial
por: Bortolus, Renata, et al.
Publicado: (2021)

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Fedorova, L., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Quadrupole Moments of $^{29}$Mg and $^{33}$Mg
por: Yordanov, Deyan Todorov, et al.
Publicado: (2019)

A combined experimental and computational study on the reaction of fluoroarenes with Mg–Mg, Mg–Zn, Mg–Al and Al–Zn bonds
por: Bakewell, Clare, et al.
Publicado: (2018)

Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China
por: Wang, Zhenhua, et al.
Publicado: (2022)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study
por: Hing Ling, Paul Kah, et al.
Publicado: (2012)

Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction
por: Tunçez, Abdullah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e9j36te8ops2u1f7rvt1g5lhdq